4.1. Analysis.

Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30

Comparison 4: Sotrovimab in non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease), Outcome 1: Mortality by day 30